Novo Nordisk is at the center of the global boom in peptide-based medicines, with its Wegovy weight-loss treatment helping transform the obesity-drug market. Yet CEO Mike Doustdar is drawing a clear line between regulated medicines and the rapidly growing market for untested peptides promoted online, suggesting that the broader “peptide craze” could create risks alongside its commercial opportunities.

Not All Peptides Are the Same

Doustdar has expressed strong support for legitimate peptide-based treatments such as Wegovy, but has warned about products being sold through unofficial channels without the same testing and regulatory oversight. The concern is particularly relevant as peptides have moved beyond traditional pharmaceutical use and become popular among consumers interested in weight loss, fitness and appearance.

For Novo Nordisk, the distinction is important. The company spends heavily on clinical trials, manufacturing standards and regulatory approval, while unapproved products can potentially reach consumers without comparable evidence on their safety, quality or effectiveness. That creates both a public-health concern and a challenge for pharmaceutical companies operating in the regulated market.

Wegovy Still Has Significant Growth Potential

The caution around unregulated peptides should not be confused with a lack of confidence in the legitimate GLP-1 market. Novo Nordisk has continued to expand its Wegovy franchise, including its oral Wegovy pill, which was launched in the United States in January 2026.

Novo has reported strong early adoption of the pill, while the broader obesity-drug market is expected to exceed $100 billion annually by 2030. At the same time, competition from Eli Lilly and its Zepbound franchise means Novo cannot rely solely on the overall expansion of the market. Product effectiveness, convenience, pricing and long-term patient use are likely to remain important competitive factors.

The Bigger Question for Investors

The investment story is therefore becoming more complicated than simply betting on the continued popularity of weight-loss drugs. Novo Nordisk must demonstrate that it can maintain demand for Wegovy while developing new treatments and responding to pricing pressure and changing consumer behavior.

The company also faces uncertainty beyond obesity. Recent setbacks involving cardiovascular drug development have raised questions about its ability to build additional growth engines outside its core diabetes and obesity franchises. On September 7, Novo Nordisk announced that it would stop two additional trials of experimental cardiovascular drug ziltivekimab after an earlier late-stage study failed to show the expected reduction in major cardiovascular events.

Outlook: The peptide market could continue expanding rapidly, but the next stage may be defined by a greater focus on regulation, safety, affordability and clinical evidence. For global and Israeli investors, Novo Nordisk provides an important example of the opportunities and risks created by the GLP-1 revolution. The company’s ability to convert Wegovy’s popularity into sustainable long-term growth, while maintaining a strong pipeline and managing competition and pricing pressure, will likely remain central to its market outlook.